These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 22440948)

  • 41. [Management of adverse events associated with molecular targeted agents].
    Fujisawa M; Sugimura Y
    Hinyokika Kiyo; 2012 Nov; 58(11):633. PubMed ID: 23254791
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Contemporary treatment of metastatic renal cell carcinoma.
    Wiechno P; Kucharz J; Sadowska M; Michalski W; Sikora-Kupis B; Jonska-Gmyrek J; Poniatowska G; Nietupski K; Ossolinski K; Demkow T
    Med Oncol; 2018 Oct; 35(12):156. PubMed ID: 30368624
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Era of molecular targeting therapy in RCC].
    Uemura H
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():480-5. PubMed ID: 23513887
    [No Abstract]   [Full Text] [Related]  

  • 44. What's new in renal cell carcinoma.
    Meng MV; Nelson H
    Bull Am Coll Surg; 2012 Aug; 97(8):65-6. PubMed ID: 22973751
    [No Abstract]   [Full Text] [Related]  

  • 45. Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma.
    Yamamoto K; Yano I
    Med Oncol; 2018 Jan; 35(2):16. PubMed ID: 29302760
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Imaging of Metastastic Renal Cell Carcinoma under Therapy with Immune Checkpoint Inhibitors].
    Notohamiprodjo M; Kopp HG; Bedke J
    Rofo; 2017 Apr; 189(4):287-292. PubMed ID: 28335045
    [No Abstract]   [Full Text] [Related]  

  • 47. Systemic therapy of metastatic renal cell carcinoma: Review of the current literature.
    Zerdes I; Tolia M; Tsoukalas N; Mitsis M; Kardamakis D; Pistevou-Gombaki K; Tsekeris P; Kyrgias G
    Urologia; 2019 Feb; 86(1):3-8. PubMed ID: 30270773
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Targeted therapy for renal cell carcinoma].
    Terai K; Horie S
    Nihon Jinzo Gakkai Shi; 2016; 58(4):568-72. PubMed ID: 27416700
    [No Abstract]   [Full Text] [Related]  

  • 49. A comparison of preferences of targeted therapy for metastatic renal cell carcinoma between the patient group and health care professional group in South Korea.
    Park MH; Jo C; Bae EY; Lee EK
    Value Health; 2012; 15(6):933-9. PubMed ID: 22999144
    [TBL] [Abstract][Full Text] [Related]  

  • 50. How to optimise treatment compliance in metastatic renal cell carcinoma with targeted agents.
    Ravaud A
    Ann Oncol; 2009 May; 20 Suppl 1():i7-12. PubMed ID: 19430007
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Next Steps: Sequencing Therapies in Metastatic Kidney Cancer in the Contemporary Era.
    Schmidt AL; Tabakin AL; Singer EA; Choueiri TK; McKay RR
    Am Soc Clin Oncol Educ Book; 2021 Mar; 41():1-11. PubMed ID: 33793313
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular-targeted therapy in advanced renal cell carcinoma based on pharmacokinetics, pharmacodynamics and pharmacogenetics: A proposed strategy.
    Tsuchiya N
    Int J Urol; 2019 Jan; 26(1):48-56. PubMed ID: 30276868
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Application of single-cell RNA sequencing in optimizing a combinatorial therapeutic strategy in metastatic renal cell carcinoma.
    Kim KT; Lee HW; Lee HO; Song HJ; Jeong da E; Shin S; Kim H; Shin Y; Nam DH; Jeong BC; Kirsch DG; Joo KM; Park WY
    Genome Biol; 2016 Apr; 17():80. PubMed ID: 27139883
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Access to targeted therapies in renal cell cancer.
    Jones R; DeSantis M
    Semin Oncol; 2013 Aug; 40(4):521-8. PubMed ID: 23972716
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evolution in upfront treatment strategies for metastatic RCC.
    Bossé D; Ong M
    Nat Rev Urol; 2020 Feb; 17(2):73-74. PubMed ID: 31911669
    [No Abstract]   [Full Text] [Related]  

  • 56. Towards Comprehensive Clinical Trial Reporting: The Value of Unpublished Data to Inform Therapeutic Decision-Making in Metastatic Renal Cell Carcinoma.
    Parmar A; Bjarnason GA; Vera-Badillo FE
    Clin Genitourin Cancer; 2019 Dec; 17(6):e1181-e1184. PubMed ID: 31606401
    [No Abstract]   [Full Text] [Related]  

  • 57. [Treatment of metastatic renal cell carcinoma using targeted therapy].
    Krabbe LM
    Urologe A; 2021 Jan; 60(1):89-93. PubMed ID: 33373009
    [No Abstract]   [Full Text] [Related]  

  • 58. Dosing modifications of targeted cancer therapies in patients with special needs: evidence and controversies.
    Ng T; Chan A
    Crit Rev Oncol Hematol; 2012 Jan; 81(1):58-74. PubMed ID: 21429761
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic accuracy in second-line renal cancer therapy.
    Bex A
    Lancet Oncol; 2015 Mar; 16(3):240-1. PubMed ID: 25681968
    [No Abstract]   [Full Text] [Related]  

  • 60. [109th Scientific Meeting of the Japanese Society of Internal Medicine: symposium: 1. Recent treatments and progress in malignant tumors--chemotherapy and molecular targeting agents. Antibody therapy; 2) Molecular target therapy for advanced renal cell carcinoma].
    Takahashi S
    Nihon Naika Gakkai Zasshi; 2012 Sep; 101(9):2514-9. PubMed ID: 23205427
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.